MediciNova has received rare paediatric disease status from the US Food and Drug Administration (FDA) for its MN-166 (ibudilast) to treat Type 1 Early Infantile Krabbe disease.
Krabbe disease is a rare genetic degenerative disorder, which is generally fatal before two years of age. It has four clinical subtypes, which can be distinguished by age of onset.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
MN-166 is a first-in-class, orally bioavailable and small molecule phosphodiesterase (PDE) -4 and -10 inhibitor and a macrophage migration inhibitory factor (MIF) inhibitor, which suppresses pro-inflammatory cytokines and promotes neurotrophic factors.
The ibudilast weakens activated glia cells, which plays a crucial role in certain neurological conditions.
The company also recently obtained orphan drug designation for ibudilast to treat Krabbe disease.
MediciNova president and CEO Dr Yuichi Iwaki said: “We are very pleased to receive Rare Pediatric Disease Designation for MN-166 for treatment of Krabbe disease.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“There is an unmet medical need for treatment of Krabbe disease in the pediatric population and we plan to work closely with the FDA and clinical experts to evaluate MN-166 in the pediatric population.”
Since 1989, the company has been marketing ibudilast in Japan and Korea to treat post-stroke complications and bronchial asthma.
MediciNova received licence for ibudilast from Kyorin Pharmaceutical for use in the treatment of relapse-remitting multiple sclerosis (RRMS).
The company also obtained additional intellectual property right for ibudilast to be used for progressive MS and other neurological conditions.
